(NASDAQ: NYXH) Nyxoah Sa's forecast annual revenue growth rate of 118.97% is forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 7.87%, and it is also forecast to beat the US market's average forecast revenue growth rate of 25.68%.
Nyxoah Sa's revenue in 2025 is $6,556,976.On average, 11 Wall Street analysts forecast NYXH's revenue for 2025 to be $297,504,853, with the lowest NYXH revenue forecast at $257,557,205, and the highest NYXH revenue forecast at $315,376,169. On average, 11 Wall Street analysts forecast NYXH's revenue for 2026 to be $1,122,025,810, with the lowest NYXH revenue forecast at $823,131,801, and the highest NYXH revenue forecast at $1,415,250,557.
In 2027, NYXH is forecast to generate $2,725,188,001 in revenue, with the lowest revenue forecast at $2,281,220,954 and the highest revenue forecast at $3,166,564,459.